Merck, a pharmaceutical company, completed the acquisition of Eyebiotech, a privately held ophthalmology-focused biotechnology company, for $3bn. “The EyeBio acquisition further diversifies our late-stage pipeline with the addition of a promising candidate based on novel biology and genetics for the treatment of certain retinal diseases. We are excited to welcome the EyeBio team and look forward to working together to advance Restoret for the patients that need it,” Dean Y. Li, Merck President of Research Laboratories.